date:Nov 16, 2015
In a Jan. 6, 2014 letter addressed to three district court judges in California and New Jersey, an FDA official said it would not be appropriate to decide the issue in litigation because it is complex, involves myriad interests and would be better suited for a public proceeding such as issuance of a regulation or formal guidance.
In the past, FDA has leaned on its longstanding policy regarding use of the term, which suggests nothing artificial or synthetic (including all color additives regard